Drug Profile
Onapristone - Context Therapeutics
Alternative Names: Apristor; AR-18; ER onapristone; IVV-1001; ONA-XR; Onapristone - Arno Therapeutics; Onapristone extended-release; ZK-299; ZK-98299Latest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Context Therapeutics; Jefferson Health; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
- Mechanism of Action Progesterone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Endometriosis; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer; Pregnancy; Prostate cancer; Uterine cancer
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase II ONWARD 221 or OATH trial in Endometrial cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-223)
- 28 Apr 2023 Memorial Sloan Kettering Cancer Center in collaboration with Context Therapeutics withdraws a phase Ib trial for Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) due to the company discontinued the development of onapristone (NCT04872608)
- 22 Mar 2023 Discontinued - Phase-0 for HER2-negative-breast-cancer (Neoadjuvant therapy) in Spain (PO)